Advertisement
IMNM vs LXEO
Which Stock Would AI Choose? Immunome (IMNM) vs. Lexeo Therapeutics (LXEO) Stock Comparison
Key Takeaways
- IMNM (Immunome) is an oncology-focused biotech advancing antibody-drug conjugates (ADCs) and a late-stage desmoid tumor candidate, while LXEO (Lexeo Therapeutics) is a genetic-medicine company targeting rare cardiovascular and neurological diseases.
- Immunome has delivered positive Phase 3 data and filed a New Drug Application (NDA) with the FDA for varegacestat, while Lexeo is positioned ahead of a binary Phase 1/2 readout for its LX2020 gene therapy program.
- Both stocks carry "Strong Buy" analyst consensus ratings, but IMNM trades near a $2 billion market capitalization versus LXEO's roughly $230 million, reflecting very different maturity and risk profiles.
- Recent momentum diverges sharply: IMNM has pulled back after a strong prior run, while LXEO has declined more than 50% year to date and trades near the value of its cash.
- For more context on each name, explore IMNM Major News and IMNM Today's Price Move, as well as LXEO Major News and LXEO Today's Price Move.
- To see how automated systems are positioning across names like these, explore Trending AI Robots.
Introduction
Both IMNM and LXEO are clinical-stage biotechnology companies, but they occupy very different corners of the sector. Immunome is building an oncology platform around antibody-drug conjugates (ADCs) and a late-stage desmoid tumor therapy, while Lexeo Therapeutics develops gene therapies for rare cardiac and neurological conditions. This stock comparison is relevant to investors weighing relative performance, market positioning, and risk across two pre-revenue biotechs at different stages of the development lifecycle. A trader focused on near-term momentum may view these names one way, while a longer-horizon investor evaluating pipeline depth and cash runway may draw different conclusions.
IMNM Overview and Recent Performance
IMNM, Immunome, Inc., is a Bothell, Washington-based biotechnology company developing oncology therapeutics, with a lead focus on ADCs and other targeted agents. Its most advanced asset, varegacestat, produced positive results in the Phase 3 RINGSIDE trial in adults with progressing desmoid tumors, showing a statistically significant reduction in the risk of disease progression or death. The company has submitted an NDA to the U.S. Food and Drug Administration (FDA), with a marketing application to the European Medicines Agency (EMA) planned.
In recent weeks, Immunome also announced FDA clearance of an investigational new drug (IND) application for IM-1340, a potential first-in-class ADC for advanced solid tumors, and has advanced several earlier-stage programs. Despite this pipeline progress, the stock has experienced a notable pullback in recent market activity, retreating from earlier highs. Analysts maintain a broadly positive view, with a "Strong Buy" consensus and an average price target well above recent trading levels. Sentiment appears influenced by both the desmoid tumor regulatory path and execution risk across an expanding early-stage portfolio.
LXEO Overview and Recent Performance
LXEO, Lexeo Therapeutics, Inc., is a New York-based clinical-stage genetic medicine company focused on therapies for genetically defined cardiovascular diseases and a subgroup of Alzheimer's disease. Its pipeline includes LX2006 for Friedreich's ataxia cardiomyopathy and LX2020 for PKP2-associated arrhythmogenic cardiomyopathy, a progressive genetic heart condition with no approved disease-modifying treatments. The company recently received FDA Regenerative Medicine Advanced Therapy designation for LX2020 and agreed to acquire Mantle Therapeutics, alongside new research collaborations.
Lexeo's share price has declined significantly over the past year and year to date, with the stock trading near the value of its cash position. Market attention is centered on a fourth-quarter data readout for the LX2020 program, an event investors view as a meaningful catalyst. Wall Street maintains a "Strong Buy" consensus with price targets implying substantial upside from current levels, but the near-term technical picture remains weak and insider selling has been reported over recent quarters.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance history, and set of securities. Because market conditions are always shifting, only a subset of these bots is well-suited to the current environment at any given moment. The Trending AI Robots page curates the bots that are performing most consistently under present conditions, allowing users to review and compare their statistics, strategies, and track records rather than sifting through the entire catalog. For traders seeking a data-driven view on how automated systems are approaching names such as IMNM and LXEO, reviewing the Trending AI Robots section is a practical starting point.
Head-to-Head Comparison
The clearest contrast between these two names is stage and therapeutic focus. Immunome operates in oncology with a late-stage asset that has already generated positive pivotal data and an active regulatory filing, giving it a nearer-term path toward potential commercialization. Lexeo operates in rare-disease gene therapy, an area with large unmet need but longer development timelines and a near-term readout that could move the stock sharply in either direction.
Market positioning also differs. Immunome's market capitalization is roughly an order of magnitude larger than Lexeo's, and its balance sheet holds a substantial cash position relative to its burn rate. Lexeo also holds meaningful cash, reported near $246 million, but trades at a valuation that implies the market is assigning limited value to its pipeline beyond that cash. On momentum, Immunome has pulled back in recent weeks after a stronger longer-term run, while Lexeo has been in a sustained downtrend, down more than half year to date. Risk profiles diverge accordingly: Immunome faces regulatory and commercial execution risk, while Lexeo faces the concentration risk of a binary clinical readout.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, and catalyst structure, Tickeron's AI would likely view Immunome as the more favorable of the two under current conditions. Immunome's positive Phase 3 data and submitted NDA provide a more defined catalyst path, and its larger market capitalization and cash position suggest comparatively greater stability despite a recent pullback. Lexeo's sharply negative trend and dependence on a single binary readout present a higher-risk profile, even with a consensus "Strong Buy" rating. These assessments are probabilistic and reflect current positioning rather than any prediction of future performance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMNM is a Hold and LXEO is a Hold.
IMNM sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for IMNM moved below the 200-day moving average on October 30, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMNM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
IMNM broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IMNM entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IMNM's RSI Indicator exited the oversold zone, 31 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on IMNM as a result. In 68 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for IMNM just turned positive on October 22, 2026. Looking at past instances where IMNM's MACD turned positive, the stock continued to rise in 37 of 45 cases over the following month. The odds of a continued upward trend are 82%.
Following a +11.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMNM advanced for three days, in 235 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. IMNM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.047) is normal, around the industry mean (3.482). P/E Ratio (-7.395) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (625.000) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 95 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
LXEO in +5.56% Uptrend, rising for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where LXEO advanced for three days, in 152 of 180 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LXEO's RSI Indicator exited the oversold zone, 12 of 15 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on LXEO as a result. In 38 of 48 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for LXEO just turned positive on October 20, 2026. Looking at past instances where LXEO's MACD turned positive, the stock continued to rise in 23 of 31 cases over the following month. The odds of a continued upward trend are 74%.
LXEO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 37 cases where LXEO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LXEO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for LXEO entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.009) is normal, around the industry mean (3.482). P/E Ratio (-3.284) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. LXEO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LXEO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
IMNM | ||
|---|---|---|
OUTLOOK RATING 1..100 | 83 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 70 Overvalued | |
PROFIT vs RISK RATING 1..100 | 95 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 62 | |
P/E GROWTH RATING 1..100 | 27 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| IMNM | LXEO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 89% | 1 day ago 80% |
| Stochastic ODDS (%) | 1 day ago 88% | 1 day ago 89% |
| Momentum ODDS (%) | 1 day ago 88% | 1 day ago 79% |
| MACD ODDS (%) | 1 day ago 82% | 1 day ago 74% |
| TrendWeek ODDS (%) | 1 day ago 85% | 1 day ago 88% |
| TrendMonth ODDS (%) | 1 day ago 85% | 1 day ago 89% |
| Advances ODDS (%) | 5 days ago 82% | 4 days ago 84% |
| Declines ODDS (%) | 3 days ago 86% | 1 day ago 90% |
| BollingerBands ODDS (%) | 1 day ago 75% | 1 day ago 80% |
| Aroon ODDS (%) | 1 day ago 80% | 1 day ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IMNM’s FA Score shows that 1 FA rating(s) are green while LXEO’s FA Score has 1 green FA rating(s).
- IMNM’s FA Score: 1 green, 4 red.
- LXEO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IMNM’s TA Score shows that 5 TA indicator(s) are bullish while LXEO’s TA Score has 5 bullish TA indicator(s).
- IMNM’s TA Score: 5 bullish, 4 bearish.
- LXEO’s TA Score: 5 bullish, 3 bearish.
Price Growth
IMNM (@Biotechnology) experienced а +2.75% price change this week, while LXEO (@Biotechnology) price change was -7.96% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.35%. For the same industry, the average monthly price growth was -10.88%, and the average quarterly price growth was -18.54%.
Reported Earning Dates
IMNM is expected to report earnings on Mar 25, 2027.
Industries' Descriptions
@Biotechnology (-2.35% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
IMNM and
Correlation & Price change
A.I.dvisor indicates that over the last year, IMNM has been loosely correlated with KYTX. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IMNM jumps, then KYTX could also see price increases.
| Ticker / NAME | Correlation To IMNM | 1D Price Change % | ||
|---|---|---|---|---|
| IMNM | 100% | +4.50% | ||
| KYTX - IMNM | 59% Loosely correlated | +5.86% | ||
| SLDB - IMNM | 53% Loosely correlated | +6.63% | ||
| EDIT - IMNM | 52% Loosely correlated | +0.78% | ||
| LXEO - IMNM | 50% Loosely correlated | -0.52% | ||
| FDMT - IMNM | 49% Loosely correlated | +8.89% | ||
More | ||||
LXEO and
Correlation & Price change
A.I.dvisor indicates that over the last year, LXEO has been loosely correlated with PRME. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if LXEO jumps, then PRME could also see price increases.
| Ticker / NAME | Correlation To LXEO | 1D Price Change % | ||
|---|---|---|---|---|
| LXEO | 100% | -0.52% | ||
| PRME - LXEO | 53% Loosely correlated | +4.49% | ||
| SLDB - LXEO | 53% Loosely correlated | +6.63% | ||
| EDIT - LXEO | 52% Loosely correlated | +0.78% | ||
| IMNM - LXEO | 51% Loosely correlated | +4.50% | ||
| RCKT - LXEO | 51% Loosely correlated | -2.05% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| VEGN | 68.52 | 0.63 | +0.92% |
| US Vegan Climate ETF (VEGN) | |||
| FFGX | 31.20 | 0.16 | +0.51% |
| Fidelity Fundamental Global ex-U.S. ETF | |||
| USFI | 23.97 | N/A | N/A |
| BrandywineGLOBAL - U.S. Fixed Income ETF (USFI) | |||
| SPTS | 28.81 | -0.01 | -0.03% |
| State Street SPDR Portfolio Short Term Treasury ETF (SPTS) | |||
| IBTM | 22.19 | -0.03 | -0.15% |
| iShares iBonds Dec 2032 Term Treasury ETF (IBTM) | |||